{"entity":{"id":"nct07641036","kind":"trial","name":"Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer","aka":[],"tldr":"A phase 1/2 trial of Fludarabine, Cyclophosphamide in gallbladder cancer, run by Beijing Biotech, now recruiting.","summary":"Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer is a phase 1/2 interventional study registered as NCT07641036 by Beijing Biotech, with 30 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide. Conditions listed: Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07641036","url":"https://clinicaltrials.gov/study/NCT07641036"}],"tags":["ctgov-ingest"],"related":[],"cancers":["gallbladder"],"sections":[],"technologies":[],"targets":[],"drugs":["fludarabine","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07641036","phase":"1/2","setting":"A Phase 1/2, Open-Label, Biomarker-Selected Study of Allogeneic Dual-Target HER2/CEACAM5 Chimeric Antigen Receptor Natural Killer Cells (EB-HC01) in Participants With Unresectable or Metastatic Cholangiocarcinoma and Other Biliary Tract Cancers","sponsor":"Beijing Biotech","enrolled":30,"outcomes":[]},"route":"/trials/nct07641036/","neighbours":{"cancer":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}